Sabina Lee

Senior Consultant at W Medical Strategy Group

Sabina Lee is a senior consultant for W Medical Strategy Group, a healthcare consulting firm that uses deep industry expertise to help a wide range of global healthcare companies achieve their mission. She has more than two decades of leading communications strategy and business development in academia, startups and government. An editorial board member for the World Asian Medical Journal (WAMJ) since 2019, she served as editor-in-chief for the New York Health Forum magazine.

Industry Trends | Emerging Technologies | Biotech Companies

Contributing Author in
AI & Digital

Disclaimer: All opinions, ideas, and thoughts expressed and posted by Contributors at BiopharmaTrend.com platform are their own personal points of view, and do not represent neither Contributor's employers, nor BiopharmaTrend.com.

Latest articles from Sabina

How to Discover a Preclinical Drug Candidate in Two Years

Recent advances in artificial intelligence (AI) has played a pivotal role in optimizing the small-molecule synthesis, standardization, scalability and CRO-based validation. Despite a dose of skepticism about the growing hype around AI, introducing greater automation to a drug design hypothesis …

How Syntekabio’s Supercomputing Enables AI-driven Drug Discovery

What is "supercomputing"? It refers to processing a massive quantity of complex data-intensive and computation-heavy problems often found in scientific or engineering projects. Using a powerful class of ‘multiple’ computer systems working in parallel, supercomputing is built into an infrastructure …

The Power of STB CLOUD in Remote AI Drug Discovery

STB CLOUD is Syntekabio’s latest cloud-based, fully automated AI platform. It’s designed for developers to engage in their drug discovery and development processes to find drug candidates easier and faster.

The State of A.I. Drug Discovery and Its Future: Small Molecules, Vaccines, and Antibodies

Artificial intelligence (A.I.) and big data in a synergistic integration have led to promising results in new drug development by drastically reducing cost and time. This trend in the biopharmaceutical market has emerged as a new industry standard as startups—each …

Democratizing Early Drug Discovery through Artificial Intelligence: Interview with Syntekabio CEO Jongsun Jung

Before the age of modern drug discovery, the pharmaceutical industry had been plagued with uncertainty and processing challenges, including the timescales, length, complexity and cost of drug discovery. So, what is transforming the biopharma industry and the future of our humanity? …